A Novel Chimeric Anti-HCV Peptide Derived from Camel Lactoferrin and Molecular Level Insight on Its Interaction with E2
- 11 Downloads
In the present study, a novel chimeric peptide was derived from camel lactoferrin designed with a considerable anti-HCV activity and its neutralization mechanism was predicted by molecular modelling tools. A novel anti-HCV peptide derived from camel lactoferrin (cLF36) was designed and expressed it recombinantly in HEK-293-T cells. Anti-viral activity of this peptide was evaluated against hepatitis C virus by Real-time PCR assay in vitro. Finally, to have a better insight into the mode of action of peptide on HCV entry inhibition, we examined the interaction of cLF36 with envelope glycoprotein E2 by molecular dynamic simulation. This chimeric peptide had significant inhibitory effects on both HCV entry (44 µg/mL) and viral replication (88 µg/mL) under in vitro (p > 0.01). Moreover, cLF36 peptide was not toxic to HEK cells as a normal cell at twofold of its anti-viral concentrations for HCV entry and even at concentrations as high as 250 µg/mL exhibited minimal hemolysis (2.5%) against human RBCs (red blood cells). The results of in silico analysis showed that cLF36 interacted with β-sandwich and front layer of E2 protein as two potential CD81 binding sites. We generated and characterized a new camel lactoferrin derived HCV inhibitors. This peptide blocked HCV entry and also intracellular HCV replication in cell culture experiment.
KeywordsAnti-HCV peptide Camel Lactoferrin Envelope glycoprotein E2 Molecular dynamic simulation
The authors would also like to express their gratitude to the Ferdowsi University of Mashhad for their support. The present study was funded by INFS (infs.gov.ir) of I.R.I with Grant No. 93,025,031.
Compliance with Ethical Standards
Conflict of interest
All Authors declare that they have no conflict of interest.
Research Involving Human and Animal Participants
Approvals to conduct experimental protocols to study hemolysis on human red cells were approved by the Committee on Publication Ethics (COPE), where this work was done. Human red cells were from volunteer Mohammad Hadi Sekhavati, who signed the informed consent for this study and is also author of this report.
- Abe K, Nozaki A, Tamura K, Ikeda M, Naka K, Dansako H, Hoshino HO, Tanaka K, Kato N (2007) Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. Microbiol Immunol 51(1):117–125. https://doi.org/10.1111/j.1348-0421.2007.tb03882.x CrossRefPubMedGoogle Scholar
- Albar AH, El-Fakharany EM, Almehdar HA, Uversky VN, Redwan EM (2017) In vitro exploration of the anti-HCV potential of the synthetic spacer peptides derived from human, bovine, and camel lactoferrins. Protein Pept Lett 24(10):909–921. https://doi.org/10.2174/0929866524666161111111320 CrossRefPubMedGoogle Scholar
- Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M (1992) Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 73(6):472–479. https://doi.org/10.1111/j.1365-2672.1992.tb05007.x CrossRefPubMedGoogle Scholar
- Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Cassarino TG, Bertoni M, Bordoli L, Schwede T (2014) SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42(1):252–258. https://doi.org/10.1093/nar/gku340 CrossRefGoogle Scholar
- Bolscher JG, Adao R, Nazmi K, van den Keybus PA, van’t Hof W, Amerongen AVN, Bastos M, Veerman EC (2009) Bactericidal activity of LFchimera is stronger and less sensitive to ionic strength than its constituent lactoferricin and lactoferrampin peptides. Biochimie 91(1):123–132. https://doi.org/10.1016/j.biochi.2008.05.019 CrossRefPubMedGoogle Scholar
- Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55(4):611–622. https://doi.org/10.1373/clinchem.2008.112797 CrossRefPubMedPubMedCentralGoogle Scholar
- El-Awady MK, Tabll AA, Redwan ERM, Youssef S, Omran MH, Thakeb F, El-Demellawy M (2005) Flow cytometric detection of hepatitis C virus antigens in infected peripheral blood leukocytes: binding and entry. World J Gastroenterol 11(33):5203–5208. https://doi.org/10.3748/wjg.v11.i33.5203 CrossRefPubMedPubMedCentralGoogle Scholar
- Flint M, McKeating JA (2000) The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol 10(2):101–117. https://doi.org/10.1002/(SICI)1099-1654(200003/04)10:2%3c101 CrossRefPubMedGoogle Scholar
- Kang JH, Lee MK, Kim KL, HAHM KS (1996) Structure–biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int J Pept Protein Res 48(4):357–363. https://doi.org/10.1111/j.1399-3011.1996.tb00852.x CrossRefPubMedGoogle Scholar
- Keck ZY, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, Patel AH, Foung SK (2014) Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412–423. PLoS Pathog 10(8):e1004297. https://doi.org/10.1371/journal.ppat.1004297 CrossRefPubMedPubMedCentralGoogle Scholar
- Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, Price AA, Yost SA, Bohannon CD, Jacob J, Grakoui A (2014) Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509(7500):381. https://doi.org/10.1038/nature13117 CrossRefPubMedPubMedCentralGoogle Scholar
- Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK (2006) Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80(17):8695–8704. https://doi.org/10.1128/JVI.00271-06 CrossRefPubMedPubMedCentralGoogle Scholar
- Pirkhezranian Z, Tanhaeian A, Mirzaii M, Sekhavati MH (2019) Expression of Enterocin-P in HEK platform: evaluation of its cytotoxic effects on cancer cell lines and its potency to interact with cell-surface glycosaminoglycan by molecular modeling. Int J Pept Res Ther. https://doi.org/10.1007/s10989-019-09956-7 CrossRefGoogle Scholar
- Redwan EM, EL-Fakharany EM, Uversky VN, Linjawi MH (2014) Screening the anti-infectivity potentials of native N-and C-lobes derived from the camel lactoferrin against hepatitis C virus. BMC Complement Altern Med 14(1):219. https://doi.org/10.1186/1472-6882-14-219 CrossRefPubMedPubMedCentralGoogle Scholar
- Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual (No. Ed. 2). Cold Spring Harbor Laboratory Press, Cold Spring HarborGoogle Scholar
- Tanhaeian A, Ahmadi FS, Sekhavati MH, Mamarabadi M (2018) Expression and purification of the main component contained in camel milk and its antimicrobial activities against bacterial plant pathogens. Probiotics Antimicrob Proteins 10(4):787–793. https://doi.org/10.1007/s12602-018-9416-9 CrossRefPubMedGoogle Scholar
- Tanhaeian A, Jaafari MR, Ahmadi FS, Vakili-Ghartavol R, Sekhavati MH (2019) Secretory expression of a chimeric peptide in Lactococcus lactis: assessment of its cytotoxic activity and a deep view on its interaction with cell-surface glycosaminoglycans by molecular modeling. Probiotics Antimicrob Proteins 11(3):1034–1041CrossRefGoogle Scholar
- Van der Kraan MI, Nazmi K, Teeken A, Groenink J, van’t Hof W, Veerman EC, Bolscher JG, Amerongen AVN (2005) Lactoferrampin, an antimicrobial peptide of bovine lactoferrin, exerts its candidacidal activity by a cluster of positively charged residues at the C-terminus in combination with a helix-facilitating N-terminal part. Biol Chem 386(2):137–142. https://doi.org/10.1515/BC.2005.017 CrossRefPubMedGoogle Scholar
- Warren L (2002) The PyMOL molecular graphics system. DeLano Scientific LLC, San Carlos, CA, USAGoogle Scholar